Brought to you by 
Kyowa Hakko licenses Asian rights to ArQule's ARQ197
06 Sep 2011
Executive Summary
Japanese pharma company Kyowa Hakko Kogyo has licensed exclusive rights from ArQule to develop and market the small-molecule c-Met inhibitor ARQ197, which is in Phase I cancer trials.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Kyowa Hakko licenses Asian rights to ArQule's ARQ197
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice